Galectin Therapeutics (NASDAQ:GALT) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a hold rating in a research report released on Wednesday morning.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research note on Friday, November 15th.

Galectin Therapeutics Stock Up 2.2 %

Shares of GALT opened at $2.82 on Wednesday. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27. The stock has a 50 day moving average price of $2.69 and a 200 day moving average price of $2.60.

Institutional Investors Weigh In On Galectin Therapeutics

Large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock valued at $4,732,000 after acquiring an additional 38,037 shares during the period. Geode Capital Management LLC raised its holdings in shares of Galectin Therapeutics by 2.5% in the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after buying an additional 20,817 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Galectin Therapeutics by 317.6% during the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after buying an additional 367,610 shares during the period. State Street Corp grew its holdings in shares of Galectin Therapeutics by 9.3% during the third quarter. State Street Corp now owns 251,014 shares of the company’s stock worth $690,000 after buying an additional 21,399 shares during the last quarter. Finally, Soltis Investment Advisors LLC acquired a new position in Galectin Therapeutics in the 3rd quarter valued at about $387,000. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.